Nitromed’s BiDil Should Not Be Second-Line Therapy, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
BiDil should be indicated for first-line treatment of chronic heart failure in African American patients, FDA says in briefing material for the Cardiovascular & Renal Drugs Advisory Committee’s June 16 review of the Nitromed product. Nitromed had requested a second-line indication. BiDil would be the first drug specifically indicated for African Americans
You may also be interested in...
Nitromed's BiDil Could Be First Drug Approved Specifically For African Americans
Company plans NDA resubmission by year-end with results from African American Heart Failure Trial in response to 2001 "approvable" letter for treatment of heart failure in African American patients. A-HeFT data show 43% survival improvement with BiDil vs. placebo.
NitroMed BiDil One Year Ahead Of Schedule Following Positive Study Results
The firm is planning for a first quarter 2005 launch after a trial in African American heart failure patients is halted early due to significant survival benefit. Initial positioning will be as an add-on to standard heart failure therapies. NitroMed sees a market opportunity of $1 bil.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications